Price
No data yet.
Social Signal Score
Revenue
$0.00Company Profile
- CEO
- Adi Zuloff-Shani
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4
- Beta
- -1.16
- Country
- CA
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -1.75
Financials
Net Income
$-907.3KEBITDA
$-2.17MFree Cash Flow
$-1.86MEPS (diluted)
$-4.56Shares Outstanding (diluted)
197.8K+5031.6%Operating Expenses
$2.17MCash & Debt
$15.93MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-3.86M | $-24.24 |
| 2024 | $0.00 | $-5.25M | $-54.24 |
| 2023 | $0.00 | $-8.61M | $-1360.56 |
| 2022 | $0.00 | $-9.93M | $-7331.52 |
| 2021 | $0.00 | $-3.66M | $-3784.80 |
| 2020 | $0.00 | $-230.1K | $-406.08 |
| 2019 | $0.00 | $-104.1K | $-270.08 |
| 2018 | $0.00 | $-198.1K | $-588.00 |
| 2017 | $0.00 | $-6.5K | $-17.20 |
Valuation
CMNDhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50-66.67%Social Signal Score
Mentions (10)
- Newsthenewswire.com·13d ago·Neutral
…, today highlighted the expansion of the U.S. intellectual property portfolio through its ongoing collaboration with Clearmind Medicine Inc. (“ Clearmind ”) (Nasdaq: CMND).
View source ↗ - Newsglobenewswire.com·19d ago·Negative
Clearmind Medicine Delivers Briefing to FDA Following Invitation to Historic Psychedelic Hearing in Washington, D.C. Mary-Elizabeth Gifford, Chief of Global Impact at Clearmind Medicine, spoke on patient access and shared insights from Clearmind's clinical trial at Yale and Johns Hopkins
View source ↗ - Newsglobenewswire.com·25d ago·Neutral
Clearmind Enrolls First Patients with Alcohol Use Disorder in CMND-100 Clinical Trial Vancouver, Canada, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), today announced the enrollment of the first patients with Alcohol Use Disorde…
View source ↗ - Newsglobenewswire.com·28d ago·Neutral
Clearmind Medicine Receives Yale IRB Approval, Enabling Patient Recruitment for Parts B and C of CMND-100 Phase I/II Trial, Following Positive Safety Results Vancouver, Canada, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company” or “Clearmind”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder…
View source ↗ - Newsglobenewswire.com·32d ago·Neutral
Clearmind Medicine Signs Definitive Agreement to Acquire 51% Stake in Wireless Charging Company for Automated Parking and Robotaxis Charging Robotics is one of the few worldwide developing innovative wireless charging systems designed specifically for automated parking facilities and autonomous mobile platforms- environments where conventional cables and plug-in infrastructure cannot operate.
View source ↗ - Newsglobenewswire.com·35d ago·Neutral
Clearmind Reaches Key Milestone: CMND-100 Phase IIa now Underway for Alcohol Use Disorder Trial, One-Third of Part C Enrolled Vancouver, Canada, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (the “Company”), a clinical-stage biopharmaceutical company advancing non-hallucinogenic psychedelic-derived neuroplastogen for scalable treatment of neuropsychiatric, metabolic, and addiction disorders including Alcohol Use Disorder (“AUD”), announced today the initiation of Pha…
View source ↗ - Newsglobenewswire.com·43d ago·Negative
Clearmind Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation U.S. publication of the patent application covering the MDMA-N-acylethanolamines combination expands intellectual property generated through the collaboration with Neurothera Labs Inc. as the FDA introduces a dedicated regulatory structure for psychedelic drug development, including MDMA
View source ↗ - Newsthenewswire.com·43d ago·Negative
…X) (the " Company " or " NeuroThera "), a clinical-stage pharmaceutical company, today announced that its ongoing collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (“ Clearmind ”) has advanced with the publication in the United States of a patent application covering a novel combination of 3,4-methylenedioxymethamphetamine (“ MDMA ”) and N-acylethanolamines, such as palmitoylethanolamide (“ PEA ”), for use in methods of treating post-traumatic stress disorder (PTSD), anxiety, and eating …
View source ↗ - Newsbenzinga.com·53d ago·Neutral
Clearmind Medicine Makes Clinical Progress in Alcohol Addiction Treatment Trial The independent Data and Safety Monitoring Board on Thursday unanimously approved Clearmind Medicine Inc. (NASDAQ:CMND) to advance its ongoing FDA-regulated Phase 1/2 clinical trial.
View source ↗ - Newsglobenewswire.com·54d ago·Neutral
Clearmind Advances CMND-100 to Alcohol Use Disorder Patients After Achieving Primary Safety Endpoint Clearmind Medicine has received Independent Data and Safety Monitoring Board (DSMB) approval to advance its clinical evaluation of CMND ‑ 100 in patients with Alcohol Use Disorder (AUD) - a key milestone in the progression of the Company ' s clinical development program.
View source ↗
Insider trading
Open-market buys and sells by CMND officers and directors.
- Bought
- $330k
- Sold
- $119k
1 trade
4 trades
- Hrt Financial Lpsold
- Hrt Financial Lpsold
- Hrt Financial Lpsold
- Hrt Financial Lpsold
- Hrt Financial Lpbought
5 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CMND.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.